{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:47:17Z","timestamp":1782276437906,"version":"3.54.5"},"reference-count":22,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo Espa\u00f1a, S.A.U.","award":["no number"],"award-info":[{"award-number":["no number"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Given the limitations of available predictive tools for poor anticoagulation control, we aimed to build and validate a novel tool and compare its predictive ability with the SAMe-TT2R2 score, using the patients from the OBJETIVO 2024 study. Methods: The original sample was randomly assigned into a training group (70%, n = 1982) for model development and a validation group (30%, n = 909) for model validation. Stratification of patients was performed based on the presence of diabetes and functional dependence on daily living activities (N with available data = 2891). The model was developed through binary logistic regression, with poor international normalized ratio (INR) control (time in therapeutic range &lt;65% using the Rosendaal method) as a dependent variable. Independent variables included renal insufficiency (glomerular filtration rate &lt; 60 mL\/min), chronic obstructive pulmonary disease, diabetes, active smoker, alcohol abuse, previous ablation, hemoglobin level, HbA1c, functional dependence in daily living activities, and number of treatments received in the last 6 months. Results: The receiver operating characteristic area under the curve (ROC AUC) was 0.579. The optimal cut-off point was 0.474 (sensitivity: 47.5%; specificity: 65.0%). Overall quality of the model for the training and validation groups was 0.49 and 0.55, respectively. The mean SAMe-TT2R2 in patients from the OBJETIVO 2024 study was 2.3. The ROC AUC for the SAMe-TT2R2 tool was 0.530. Overall quality of SAMe-TT2R2 for the present population was 0.51. Conclusions: None of the models presently tested reached the minimum threshold considered acceptable for discriminative ability. To date, utility of different models to predict poor anticoagulation control seems far from optimal in clinical practice.<\/jats:p>","DOI":"10.3390\/jcm15134860","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:09:17Z","timestamp":1782270557000},"page":"4860","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Novel Predictive Tool for Poor Anticoagulation Control in Patients on Vitamin K Antagonists in Spain: An Exploratory Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6135-7685","authenticated-orcid":false,"given":"Vivencio","family":"Barrios","sequence":"first","affiliation":[{"name":"Cardiology Department, Ramon y Cajal University Hospital, University of Alcal\u00e1, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Anguita S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Reina Sofia University Hospital, University of C\u00f3rdoba, Maim\u00f3nides Biomedical Research Institute of C\u00f3rdoba (IMIBIC), 14004 C\u00f3rdoba, Spain"},{"name":"Cardiology Department, Cardiovascular Diseases Biomedical Research Networking Centre (CIBERCV), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rodr\u00edguez Padial","sequence":"additional","affiliation":[{"name":"Cardiology Department, Toledo University Hospital, Servicio de Salud de Castilla-La Mancha (SESCAM), 45007 Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e13070","DOI":"10.1111\/ijcp.13070","article-title":"Epidemiology of atrial fibrillation","volume":"72","author":"Zulkifly","year":"2018","journal-title":"Int. J. Clin. Pract."},{"key":"ref_2","first-page":"259","article-title":"Prevalence of atrial fibrillation in Spain. OFRECE study results","volume":"67","author":"Muniz","year":"2014","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/asheducation-2018.1.332","article-title":"Optimizing quality care for the oral vitamin K antagonists (VKAs)","volume":"2018","author":"Pengo","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"107031","DOI":"10.1016\/j.medcli.2025.107031","article-title":"Quality of anticoagulation with vitamin K antagonists in Spain: A systematic review with meta-analysis of national registries","volume":"165","author":"Menichelli","year":"2025","journal-title":"Med. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT2R2 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/europace\/euu353","article-title":"Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists","volume":"17","author":"Abumuaileq","year":"2015","journal-title":"Europace"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijcard.2017.09.115","article-title":"Validation of the Same-TT2R2 Score in a Multiethnic Cohort of Asian Patients with Atrial Fibrillation on Warfarin Therapy: A Multicenter Study","volume":"249","author":"Khaw","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/10600280231166643","article-title":"SAMe-TT2R2 to Predict Clinical Outcomes and Time in Therapeutic Range in Patients on Vitamin K Antagonists: A Systematic Review and Meta-Analysis","volume":"58","author":"Incomenoy","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1160\/TH15-02-0169","article-title":"Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists","volume":"114","author":"Bertomeu","year":"2015","journal-title":"Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.amjmed.2015.05.036","article-title":"The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective \u2018Real-world\u2019 Inception Cohort Study","volume":"128","author":"Cancio","year":"2015","journal-title":"Am. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0300-8932(25)00457-9","article-title":"4019-6. Situaci\u00f3n actual del control de la anticoagulaci\u00f3n en pacientes con fibrilaci\u00f3n auricular no valvular tratados con antagonistas de la vitamina k respecto a la evidencia previa de mal control en Espa\u00f1a: Estudio OBJETIVO 2024","volume":"77","author":"Barrios","year":"2024","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Barrios, V., Anguita S\u00e1nchez, M., and Rodr\u00edguez Padial, L. (2026). Prevalence and persistence of suboptimal anticoagulation control with vitamin K antagonists in Spain. Rev. Esp. Cardiol. (Engl. Ed.), Online ahead of print.","DOI":"10.1016\/j.rec.2026.02.004"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101821","DOI":"10.1016\/j.semerg.2022.101821","article-title":"ROC curve","volume":"49","year":"2023","journal-title":"Semergen"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/europace\/eux314","article-title":"Quality of oral anticoagulation with vitamin K antagonists in \u2018real-world\u2019 patients with atrial fibrillation: A report from the prospective multicentre FANTASIIA registry","volume":"20","author":"Roldan","year":"2018","journal-title":"Europace"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1185\/03007995.2016.1164676","article-title":"Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: A nationwide study in Spain","volume":"32","author":"Barrios","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_18","first-page":"453","article-title":"SAMe-TT2R2 Score Does Not Predict Time in Therapeutic Range in Atrial Fibrillation Patients After Hospitalization for Acute Decompensated Heart Failure","volume":"69","author":"Puche","year":"2016","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2217\/fca-2020-0122","article-title":"A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: The DAFNE score","volume":"17","author":"Barrios","year":"2021","journal-title":"Future Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/FPC.0000000000000244","article-title":"Genetic determinants of variability in warfarin response after the dose-titration phase","volume":"26","author":"Iwuchukwu","year":"2016","journal-title":"Pharmacogenet. Genom."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s11239-025-03203-1","article-title":"Clinical, genetic, and nutritional determinants of INR: Role of plasma warfarin and hydroxylated metabolite levels in anticoagulated Mexican patients","volume":"59","year":"2025","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ajhg.2007.10.002","article-title":"Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations","volume":"82","author":"Scott","year":"2008","journal-title":"Am. J. Hum. Genet."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4860\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:01:15Z","timestamp":1782273675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":22,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15134860"],"URL":"https:\/\/doi.org\/10.3390\/jcm15134860","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}